中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

Simcere Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis

Jan. 12, 2026， Simcere Pharmaceutical Group (2096.HK) announced positive topline results from a Phase III clinical trial evaluating zemprociti...

2026-01-16
Envafolimab Submits New Drug Application for Advanced Biliary Tract Cancer, Accepted for Review by NMPA

Recently, Simcere Pharmaceutical Group (2096.HK)’s innovative oncology subsidiary, Simcere Zaiming, announced that the New Drug Application (NDA) for ...

2026-01-16
Phase III clinical trial (SCORES) data of Suvemcitug published in Nature Cancer

On January 9, 2026, Nature Cancer published the complete Phase III clinical trial (SCORES) data for China’s innovative Class 1 anti-tumor drug, Suvemc...

2026-01-16
TASTE-2 Study Published in The BMJ: Combination of Cerebral Cytoprotection and Thrombectomy Significantly Reduces Post-Stroke Disability

On January 7, 2026, the full results of the large-scale TASTE-2 clinical study were published in The British Medical Journal (BMJ, Impact Factor: 42.7...

2026-01-09
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Terms of UsePrivacy Policy

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.